Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder-Reference-Cited by-同舟云学术

Ganaxolone: First FDA-approved Medicine for the Treatment of Seizures Associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder

Published:2024-02 Issue:4 Volume:31 Page:388-392
ISSN:0929-8673
Container-title:Current Medicinal Chemistry
language:en
Short-container-title:CMC

Author:

De Surya K.¹²

Affiliation:

1. Department of Chemistry, Conju-Probe, San Diego, CA, USA

2. Bharath University, Chennai, Tamil Nadu, 600126, India

Abstract

Abstract: The neurosteroids progesterone and allopregnanolone control numerous neuroprotective functions in neural tissues, including inhibition of epileptic seizures and cell death. Ganaxolone (3α-hydroxy-3β-methyl-5α-pregnan-20-one) (GNX) is the 3β- methylated synthetic analog of allopregnanolone and an allosteric GABAA positive modulator. Ganaxolone reduces the frequency of CDD-associated seizures.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry

Reference25 articles.

1. Knight E.M.P.; Amin S.; Bahi-Buisson N.; Benke T.A.; Cross J.H.; Demarest S.T.; Olson H.E.; Specchio N.; Fleming T.R.; Aimetti A.A.; Gasior M.; Devinsky O.; Belousova E.; Belyaev O.; Ben-Zeev B.; Brunklaus A.; Ciliberto M.A.; Darra F.; Davis R.; De Giorgis V.; Doronina O.; Fahey M.; Guerrini R.; Heydemann P.; Khaletskaya O.; Lisewski P.; Marsh E.D.; Moosa A.N.; Perry S.; Philip S.; Rajaraman R.R.; Renfroe B.; Saneto R.P.; Scheffer I.E.; Sogawa Y.; Suter B.; Sweney M.T.; Tarquinio D.; Veggiotti P.; Wallace G.; Weisenberg J.; Wilfong A.; Wirrell E.C.; Zafar M.; Zolnowska M.; Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: Results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2022,21(5),417-427

2. Olson H.E.; Demarest S.T.; Pestana-Knight E.M.; Swanson L.C.; Iqbal S.; Lal D.; Leonard H.; Cross J.H.; Devinsky O.; Benke T.A.; Cyclin-dependent kinase-like 5 deficiency disorder: Clinical review. Pediatr Neurol 2019,97,18-25

3. Hong W.; Haviland I.; Pestana-Knight E.; Weisenberg J.L.; Demarest S.; Marsh E.D.; Olson H.E.; CDKL5 deficiency disorder-related epilepsy: A review of current and emerging treatment. CNS Drugs 2022,36(6),591-604

4. Leonard H.; Downs J.; Benke T.A.; Swanson L.; Olson H.; Demarest S.; CDKL5 deficiency disorder: Clinical features, diagnosis, and management. Lancet Neurol 2022,21(6),563-576

5. Perucca E.; French J.; Bialer M.; Development of new antiepileptic drugs: Challenges, incentives, and recent advances. Lancet Neurol 2007,6(9),793-804

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population;Journal of Clinical Medicine;2024-06-18

2. Pharmacodynamic rationale for the choice of antiseizure medications in the paediatric population;Neurotherapeutics;2024-04

3. Intravenous Ganaxolone: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy Adults;Clinical Pharmacology in Drug Development;2024-01-17

4. Drugs Acting on Central Nervous System;Essentials of Pharmacodynamics and Drug Action;2024

5. Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression;Dialogues in Clinical Neuroscience;2023-10-05